Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for CD20xCD3 bispecific Lunsumio VELO ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

Scientists have found a link between the quality of your gluteus maximus muscles and your risk of developing type 2 diabetes. Harry Bullmore discovers that the consequences actually go a lot deeper ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

Dr Sharma explains how high concentrations of visceral fat interferes during surgical procedures. He suggests bariatric surgery as an effective way to curb it.

For those willing to take a chance, let's consider two biotech stocks that could eventually become solid, well-established drugmakers: CRISPR Therapeutics ( CRSP 0.76%) and Viking Therapeutics ( VKTX ...

The body undergoes a number of physiological changes that results in slower metabolism and greater storage of fat, according to Dr Sethi.